This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bunnell, B. A.
Right arrow Articles by Morgan, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bunnell, B. A.
Right arrow Articles by Morgan, R. A.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, January 1998, p. 42-56, Vol. 11, No. 1
0893-8512/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Gene Therapy for Infectious Diseases

Bruce A. Bunnelldagger and Richard A. Morgan*

Clinical Gene Therapy Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892-1851

Gene therapy is being investigated as an alternative treatment for a wide range of infectious diseases that are not amenable to standard clinical management. Approaches to gene therapy for infectious diseases can be divided into three broad categories: (i) gene therapies based on nucleic acid moieties, including antisense DNA or RNA, RNA decoys, and catalytic RNA moieties (ribozymes); (ii) protein approaches such as transdominant negative proteins and single-chain antibodies; and (iii) immunotherapeutic approaches involving genetic vaccines or pathogen-specific lymphocytes. It is further possible that combinations of the aforementioned approaches will be used simultaneously to inhibit multiple stages of the life cycle of the infectious agent.

* Corresponding author. Mailing address: Clinical Gene Therapy Branch, National Human Genome Research Institute, Building 10, Room 10C103, 9000 Rockville Pike, Bethesda, MD 20892-1851. Phone: (301) 402-1830. Fax: (301) 402-1921. E-mail: rmorgan{at}nhgri.nih.gov.

dagger Present address: Institute of Molecular Medicine, W512 Children's Hospital Research Foundation, The Ohio State University, Columbus, OH 43205-2696.

Clinical Microbiology Reviews, January 1998, p. 42-56, Vol. 11, No. 1
0893-8512/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Habu, Y., Miyano-Kurosaki, N., Kitano, M., Endo, Y., Yukita, M., Ohira, S., Takaku, H., Nashimoto, M., Takaku, H. (2005). Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL. Nucleic Acids Res 33: 235-243 [Abstract] [Full Text]  
  • Schumann, G., Hermankova, M., Cannon, K., Mankowski, J. L., Boeke, J. D. (2001). Therapeutic Effect of a Gag-Nuclease Fusion Protein against Retroviral Infection In Vivo. J. Virol. 75: 7030-7041 [Abstract] [Full Text]  
  • Nielsen, H. V., Lauemoller, S. L., Christiansen, L., Buus, S., Fomsgaard, A., Petersen, E. (1999). Complete Protection against Lethal Toxoplasma gondii Infection in Mice Immunized with a Plasmid Encoding the SAG1 Gene. Infect. Immun. 67: 6358-6363 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»